Linezolid for the treatment of skin and soft-tissue infections

References

• Vinh DC, Embil JM. Rapidly progressive soft tissue infections. Lancet Infect. Dis.5(8), 501–513 (2005).
   PubMed Web of Science ®Google Scholar
• Kirby JT, Mutnick AH, Jones RN, Biedenbach DJ, Pfaller MA. Geographic variations in garenoxacin (BMS284756) activity tested against pathogens associated with skin and soft-tissue infections: report from the SENTRY Antimicrobial Surveillance Program (2000). Diagn. Microbiol. Infect. Dis.43(4), 303–309 (2002).
   PubMed Web of Science ®Google Scholar
• Jones RN, Low DE, Pfaller MA. Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant Gram-positive bacteria: the role of streptogramins and other newer compounds. Diagn. Microbiol. Infect. Dis.33(2), 101–112 (1999).
   PubMed Web of Science ®Google Scholar
• Low DE, Keller N, Barth A, Jones RN. Clinical prevalence, antimicrobial susceptibility, and geographic resistance patterns of enterococci: results from the SENTRY Antimicrobial Surveillance Program, 1997–1999. Clin. Infect. Dis.32(Suppl. 2), S133–S145 (2001).
   PubMed Web of Science ®Google Scholar
• Smith TL, Pearson ML, Wilcox KR et al. Emergence of vancomycin resistance in Staphylococcus aureus. Glycopeptide-Intermediate Staphylococcus aureus Working Group. N. Engl. J. Med.340(7), 493–501 (1999).
   PubMed Web of Science ®Google Scholar
• Moran GJ, Amii RN, Abrahamian FM, Talan DA. Methicillin-resistant Staphylococcus aureus in community-acquired skin infections. Emerg. Infect. Dis.11(6), 928–930 (2005).
   PubMed Web of Science ®Google Scholar
• Pallares R, Dick R, Wenzel RP, Adams JR, Nettleman MD. Trends in antimicrobial utilization at a tertiary teaching hospital during a 15 year period (1978–1992). Infect. Control Hosp. Epidemiol.14(7), 376–382 (1993).
   PubMed Web of Science ®Google Scholar
• Aucken HM, Warner M, Ganner M et al. Twenty months of screening for glycopeptide-intermediate Staphylococcus aureus.J. Antimicrob. Chemother.46(4), 639–640 (2000).
   PubMedGoogle Scholar
• Reacher MH, Shah A, Livermore DM et al. Bacteraemia and antibiotic resistance of its pathogens reported in England and Wales between 1990 and 1998: trend analysis. BMJ320(7229), 213–216 (2000).
   PubMed Web of Science ®Google Scholar
• Hancock RE. Mechanisms of action of newer antibiotics for Gram-positive pathogens. Lancet Infect. Dis.5(4), 209–218 (2005).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Dotter B, Madaras-Kelly K. A review of linezolid: the first oxazolidinone antibiotic. Expert Rev. Anti Infect. Ther.2(1), 51–59 (2004).
   PubMedGoogle Scholar
• Shinabarger DL, Marotti KR, Murray RW et al. Mechanism of action of oxazolidinones: effects of linezolid and eperezolid on translation reactions. Antimicrob. Agents Chemother.41(10), 2132–2136 (1997).
   PubMed Web of Science ®Google Scholar
• Daly JS, Eliopoulos GM, Willey S, Moellering RC Jr. Mechanism of action and in vitro and in vivo activities of S-6123, a new oxazolidinone compound. Antimicrob. Agents Chemother.32(9), 1341–1346 (1988).
   PubMedGoogle Scholar
• Stevens DL, Bryant AE, Hackett SP. Antibiotic effects on bacterial viability, toxin production, and host response. Clin. Infect. Dis.20(Suppl. 2), S154–S157 (1995).
   PubMed Web of Science ®Google Scholar
• Swaney SM, Aoki H, Ganoza MC, Shinabarger DL. The oxazolidinone linezolid inhibits initiation of protein synthesis in bacteria. Antimicrob. Agents Chemother.42(12), 3251–3255 (1998).
   PubMed Web of Science ®Google Scholar
• Schweiger ES, Weinberg JM. Novel antibacterial agents for skin and skin structure infections. J. Am. Acad. Dermatol.50(3), 331–340; quiz 341–332 (2004).
   PubMed Web of Science ®Google Scholar
• Stalker DJ, Jungbluth GL. Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clin. Pharmacokinet.42(13), 1129–1140 (2003).
   PubMed Web of Science ®Google Scholar
• Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J. Antimicrob. Chemother.51(5), 1239–1246 (2003).
   PubMed Web of Science ®Google Scholar
• MacGowan AP. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. J. Antimicrob. Chemother.51(Suppl. 2), ii17–ii25 (2003).
   PubMed Web of Science ®Google Scholar
• Slatter JG, Stalker DJ, Feenstra KL et al. Pharmacokinetics, metabolism, and excretion of linezolid following an oral dose of [(14)C] linezolid to healthy human subjects. Drug Metab. Dispos.29(8), 1136–1145 (2001).
   PubMed Web of Science ®Google Scholar
• Craig WA. Basic pharmacodynamics of antibacterials with clinical applications to the use of β-lactams, glycopeptides, and linezolid. Infect. Dis. Clin. North Am.17(3), 479–501 (2003).
   PubMed Web of Science ®Google Scholar
• Taylor JJ, Estes LL, Wilson JW. Linezolid and serotonergic drug interactions. Clin. Infect. Dis.43(10), 1371 (2006).
   PubMed Web of Science ®Google Scholar
• Eliopoulos GM, Wennersten CB, Gold HS, Moellering RC Jr. In vitro activities in new oxazolidinone antimicrobial agents against enterococci. Antimicrob. Agents Chemother.40(7), 1745–1747 (1996).
   PubMed Web of Science ®Google Scholar
• Ford CW, Hamel JC, Wilson DM et al.In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob. Agents Chemother.40(6), 1508–1513 (1996).
   PubMed Web of Science ®Google Scholar
• Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR. In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob. Agents Chemother.43(8), 2059–2062 (1999).
   PubMed Web of Science ®Google Scholar
• Zurenko GE, Yagi BH, Schaadt RD et al.In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob. Agents Chemother.40(4), 839–845 (1996).
   PubMed Web of Science ®Google Scholar
• Ahkee S, Smith S, Newman D, Ritter W, Burke J, Ramirez JA. Early switch from intravenous to oral antibiotics in hospitalized patients with infections: a 6 month prospective study. Pharmacotherapy17(3), 569–575 (1997).
   PubMedGoogle Scholar
• Cox NH, Colver GB, Paterson WD. Management and morbidity of cellulitis of the leg. J. R. Soc. Med.91(12), 634–637 (1998).
   PubMed Web of Science ®Google Scholar
• French G. Safety and tolerability of linezolid. J. Antimicrob. Chemother.51(Suppl. 2), ii45–ii53 (2003).
   PubMed Web of Science ®Google Scholar
• Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R. Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob. Agents Chemother.45(6), 1843–1846 (2001).
   PubMed Web of Science ®Google Scholar
• Cepeda JA, Whitehouse T, Cooper B et al. Linezolid versus teicoplanin in the treatment of Gram-positive infections in the critically ill: a randomized, double-blind, multicentre study. J. Antimicrob. Chemother.53(2), 345–355 (2004).
   PubMed Web of Science ®Google Scholar
• Dehghanyar P, Burger C, Zeitlinger M et al. Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob. Agents Chemother.49(6), 2367–2371 (2005).
   PubMed Web of Science ®Google Scholar
• Stein GE, Schooley SL, Peloquin CA et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann. Pharmacother.39(3), 427–432 (2005).
   PubMed Web of Science ®Google Scholar
• Wilson AP. Clinical pharmacokinetics of teicoplanin. Clin. Pharmacokinet.39(3), 167–183 (2000).
   PubMed Web of Science ®Google Scholar
• Ament PW, Jamshed N, Horne JP. Linezolid: its role in the treatment of Gram-positive, drug-resistant bacterial infections. Am. Fam. Physician65(4), 663–670 (2002).
   PubMed Web of Science ®Google Scholar
• Kearns GL, Abdel-Rahman SM, Blumer JL et al. Single dose pharmacokinetics of linezolid in infants and children. Pediatr. Infect. Dis. J.19(12), 1178–1184 (2000).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin. Infect. Dis.41(10), 1373–1406 (2005).
   PubMed Web of Science ®Google Scholar
• Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest118(1), 146–155 (2000).
   PubMed Web of Science ®Google Scholar
• Kollef MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin. Infect. Dis.31(Suppl. 4), S131–S138 (2000).
   Google Scholar
• Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest115(2), 462–474 (1999).
   PubMed Web of Science ®Google Scholar
• Kollef MH, Ward S, Sherman G et al. Inadequate treatment of nosocomial infections is associated with certain empiric antibiotic choices. Crit. Care Med.28(10), 3456–3464 (2000).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Smith LG, Bruss JB et al. Randomized comparison of linezolid (PNU-100766) versus oxacillin–dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother.44(12), 3408–3413 (2000).
   PubMed Web of Science ®Google Scholar
• Mangano R, Zotti G, Voros D, Molinari M. Comparison of linezolid and flucloxacillin sodium in the treatment of complicated skin infections: analysis of European and South African patients in a Phase III trial. Presented at: Third International Meeting on the Therapy of Infections.Florence, Italy, 22–24 November, 2000.
   Google Scholar
• Kaplan SL, Deville JG, Yogev R et al. Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children. Pediatr. Infect. Dis. J.22(8), 677–686 (2003).
   PubMed Web of Science ®Google Scholar
• Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin. Infect. Dis.34(11), 1481–1490 (2002).
   PubMed Web of Science ®Google Scholar
• Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob. Agents Chemother.49(6), 2260–2266 (2005).
   PubMed Web of Science ®Google Scholar
• Wible K, Tregnaghi M, Bruss J, Fleishaker D, Naberhuis-Stehouwer S, Hilty M. Linezolid versus cefadroxil in the treatment of skin and skin structure infections in children. Pediatr. Infect. Dis. J.22(4), 315–323 (2003).
   PubMed Web of Science ®Google Scholar
• Velissariou IM. Use of linezolid in children: an overview of recent advances. Expert Rev. Anti Infect. Ther.4(6), 947–952 (2006).
   PubMedGoogle Scholar
• Falagas ME, Siempos, II, Vardakas KZ. Linezolid versus glycopeptide or β-lactam for treatment of Gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect. Dis.8(1), 53–66 (2008).
   PubMed Web of Science ®Google Scholar
• Weigelt J, Kaafarani HM, Itani KM, Swanson RN. Linezolid eradicates MRSA better than vancomycin from surgical-site infections. Am. J. Surg.188(6), 760–766 (2004).
   PubMed Web of Science ®Google Scholar
• Hayman S, Wilson AP, Singer M, Bellingan G. Effect of linezolid and teicoplanin on skin staphylococci. J. Antimicrob. Chemother.59(6), 1281–1282 (2007).
   PubMedGoogle Scholar
• Roberts S, Chambers S. Diagnosis and management of Staphylococcus aureus infections of the skin and soft tissue. Intern. Med. J.35(Suppl. 2), S97–S105 (2005).
   PubMed Web of Science ®Google Scholar
• Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J. Antimicrob. Chemother.52(Suppl. 1), i3–i17 (2003).
   PubMedGoogle Scholar
• Grayson ML. The treatment triangle for staphylococcal infections. N. Engl. J. Med.355(7), 724–727 (2006).
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Itani K, Norden C. Treating foot infections in diabetic patients: a randomized, multicenter, open-label trial of linezolid versus ampicillin–sulbactam/amoxicillin–clavulanate. Clin. Infect. Dis.38(1), 17–24 (2004).
   PubMed Web of Science ®Google Scholar
• Lipsky BA. New developments in diagnosing and treating diabetic foot infections. Diabetes Metab. Res. Rev. (2008).
   Google Scholar
• Vardakas KZ, Horianopoulou M, Falagas ME. Factors associated with treatment failure in patients with diabetic foot infections: An analysis of data from randomized controlled trials. Diabetes Res. Clin. Pract.80(3), 344–351(2008).
   PubMed Web of Science ®Google Scholar
• Lipsky BA. Empirical therapy for diabetic foot infections: are there clinical clues to guide antibiotic selection? Clin. Microbiol. Infect.13(4), 351–353 (2007).
   PubMed Web of Science ®Google Scholar
• Rubinstein E, Isturiz R, Standiford HC et al. Worldwide assessment of linezolid’s clinical safety and tolerability: comparator-controlled Phase III studies. Antimicrob. Agents Chemother.47(6), 1824–1831 (2003).
   PubMed Web of Science ®Google Scholar
• Saiman L, Goldfarb J, Kaplan SA et al. Safety and tolerability of linezolid in children. Pediatr. Infect. Dis. J.22(Suppl. 9), S193–S200 (2003).
   PubMed Web of Science ®Google Scholar
• Jauregui LE, Babazadeh S, Seltzer E et al. Randomized, double-blind comparison of once-weekly dalbavancin versus twice-daily linezolid therapy for the treatment of complicated skin and skin structure infections. Clin. Infect. Dis.41(10), 1407–1415 (2005).
   PubMed Web of Science ®Google Scholar
• Wilcox M, Nathwani D, Dryden M. Linezolid compared with teicoplanin for the treatment of suspected or proven Gram-positive infections. J. Antimicrob. Chemother.53(2), 335–344 (2004).
   PubMed Web of Science ®Google Scholar
• Clemett D, Markham A. Linezolid. Drugs59(4), 815–827; discussion 828 (2000).
   PubMed Web of Science ®Google Scholar
• Gerson SL, Kaplan SL, Bruss JB et al. Hematologic effects of linezolid: summary of clinical experience. Antimicrob. Agents Chemother.46(8), 2723–2726 (2002).
   PubMed Web of Science ®Google Scholar
• Green SL, Maddox JC, Huttenbach ED. Linezolid and reversible myelosuppression. JAMA285(10), 1291 (2001).
   PubMed Web of Science ®Google Scholar
• Bressler AM, Zimmer SM, Gilmore JL, Somani J. Peripheral neuropathy associated with prolonged use of linezolid. Lancet Infect. Dis.4(8), 528–531 (2004).
   PubMed Web of Science ®Google Scholar
• Lee E, Burger S, Shah J et al. Linezolid-associated toxic optic neuropathy: a report of 2 cases. Clin. Infect. Dis.37(10), 1389–1391 (2003).
   PubMed Web of Science ®Google Scholar
• Bouza E, Munoz P. Linezolid: pharmacokinetic characteristics and clinical studies. Clin. Microbiol. Infect.7(Suppl. 4) 75–82 (2001).
   PubMed Web of Science ®Google Scholar
• Kopterides P, Papadomichelakis E, Armaganidis A. Linezolid use associated with lactic acidosis. Scand. J. Infect. Dis.37(2), 153–154 (2005).
   PubMed Web of Science ®Google Scholar
• Nathwani D, Malek M. Cost considerations in the evaluation of new therapies for gram-positive bacteria. Int. J. Antimicrob. Agents13(2), 71–78 (1999).
   PubMedGoogle Scholar
• Engemann JJ, Carmeli Y, Cosgrove SE et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin. Infect. Dis.36(5), 592–598 (2003).
   PubMed Web of Science ®Google Scholar
• Li Z, Willke RJ, Pinto LA et al. Comparison of length of hospital stay for patients with known or suspected methicillin-resistant Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacotherapy21(3), 263–274 (2001).
   PubMed Web of Science ®Google Scholar
• Willke RJ, Glick HA, Li JZ, Rittenhouse BE. Effects of linezolid on hospital length of stay compared with vancomycin in treatment of methicillin-resistant Staphylococcus infections. An application of multivariate survival analysis. Int. J. Technol. Assess. Health Care18(3), 540–554 (2002).
   PubMedGoogle Scholar
• Itani KM, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int. J. Antimicrob. Agents26(6), 442–448 (2005).
   PubMed Web of Science ®Google Scholar
• Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg. Infect. (Larchmt)4(1), 57–70 (2003).
   PubMedGoogle Scholar
• Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus.Am. J. Surg.189(4), 425–428 (2005).
   PubMed Web of Science ®Google Scholar
• Vinken AG, Li JZ, Balan DA, Rittenhouse BE, Willke RJ, Goodman C. Comparison of linezolid with oxacillin or vancomycin in the empiric treatment of cellulitis in US hospitals. Am. J. Ther.10(4), 264–274 (2003).
   PubMedGoogle Scholar
• Seedat J, Zick G, Klare I, Konstabel C, Weiler N, Sahly H. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection. Antimicrob. Agents Chemother.50(12), 4217–4219 (2006).
   PubMed Web of Science ®Google Scholar
• Wolter N, Smith AM, Farrell DJ et al. Novel mechanism of resistance to oxazolidinones, macrolides, and chloramphenicol in ribosomal protein L4 of the pneumococcus. Antimicrob. Agents Chemother.49(8), 3554–3557 (2005).
   PubMed Web of Science ®Google Scholar
• Herrero IA, Issa NC, Patel R. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.N. Engl. J. Med.346(11), 867–869 (2002).
   PubMed Web of Science ®Google Scholar
• Scheinfeld N. A comparison of available and investigational antibiotics for complicated skin infections and treatment-resistant Staphylococcus aureus and enterococcus. J. Drugs Dermatol.6(1), 97–103 (2007).
   PubMedGoogle Scholar
• Falagas ME, Kopterides P. Old antibiotics for infections in critically ill patients. Curr. Opin. Crit. Care13(5), 592–597 (2007).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Michalopoulos A. Polymyxins: old antibiotics are back. Lancet367(9511), 633–634 (2006).
   PubMed Web of Science ®Google Scholar
• Bliziotis IA, Ntziora F, Lawrence KR, Falagas ME. Rifampin as adjuvant treatment of Gram-positive bacterial infections: a systematic review of comparative clinical trials. Eur. J. Clin. Microbiol. Infect. Dis.26(12), 849–856 (2007).
   PubMedGoogle Scholar
• Falagas ME, Bliziotis IA, Fragoulis KN. Oral rifampin for eradication of Staphylococcus aureus carriage from healthy and sick populations: a systematic review of the evidence from comparative trials. Am. J. Infect. Control35(2), 106–114 (2007).
   PubMed Web of Science ®Google Scholar
• Falagas ME, Giannopoulou KP, Kokolakis GN, Rafailidis PI. Fosfomycin: use beyond urinary tract and gastrointestinal infections. Clin. Infect. Dis.46(7), 1069–1077 (2008).
   PubMed Web of Science ®Google Scholar
• Cammarata S, McConnell-Martin MA, Oliphant TH, Todd WM, Hafkin B, Batts DH. Efficacy of linezolid in gram-positive infections: results from two Phase II trials. Pharmacotherapy20, 349 (2000).
   Google Scholar
• Duvall S, Bruss J, McConnell-Martin M, Todd W, Hafkin B. Comparison of oral linezolid to oral clarithromycin in the treatment of uncomoplicated skin infections: results from a multinational Phase III trial. Presented at: 9th International Congress of Infectious Diseases. Buenos Aires, Argentina, 10–13 April 2000.
   Google Scholar